Free Physician Assistant CME

Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma consists of two presentations with discussion: Optimal Nursing Strategies to Manage Pediatric Patients with High-Risk Neuroblastoma and Recurrent/Refractory Disease of Pediatric Neuroblastoma: Enhancing the Role of the Nurse.

At the conclusion of Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you will be able to:
• Review the fundamentals of diagnosing, treating, and managing high-risk pediatric neuroblastoma
• Examine strategies to improve supportive care for children with high-risk neuroblastoma
• Examine the aspects of parental decision-making regarding appropriate care for children with recurrent/refractory neuroblastoma
• Plan strategies to improve the dialogue and working relationship with parents/caregivers of pediatric patients regarding the goals of care through the treatment continuum and beyond

Nursing Educational Objective:
After completing Advances in Nursing Care for Pediatric Patients with High-Risk Neuroblastoma, you should be able to:
• Provide appropriate care and counsel for patients and their families

Target Audiences:
This program is intended for pediatric oncology nurses, pediatric nurses, oncology nurses, nurse practitioners, nurse managers, infusion nurses, research nurses, physician assistants, and other health care providers who care for or have an interest in pediatric patients with high-risk neuroblastoma.

Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, mechanical, behavioral, and surgical interventions; biofeedback; and clinical pearls and difficult-to-treat cases.

After reviewing Chronic Idiopathic Constipation (CIC), you will be able to:
• Describe the pathophysiology of chronic idiopathic constipation
• Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients
• Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation.
• Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatment

Target Audience:
Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation.

Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.

After completing this course, you will better be able to:

• Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
• Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
• Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
• Design an evidence-based treatment plan for a patient with aHUS

Target Audience: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.